BTK and glioblastoma: Based on this extensive evidence and the findings of our previous work on BTK and its potential synergism with mTOR inhibition, we hypothesized that targeting this particular molecule would effectively suppress the CSCs-like phenotype of GBM and, through combination therapy, ultimately reduce angiogenesis and improve the vascular normalization of GBM tumors.